Madison Investment Advisors LLC Makes New $979,000 Investment in Genmab A/S (NASDAQ:GMAB)

Madison Investment Advisors LLC bought a new position in Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 46,904 shares of the company's stock, valued at approximately $979,000.

Several other large investors also recently added to or reduced their stakes in GMAB. Charles Schwab Investment Management Inc. increased its position in Genmab A/S by 94.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company's stock worth $636,000 after acquiring an additional 12,654 shares during the period. AIMZ Investment Advisors LLC acquired a new stake in Genmab A/S during the fourth quarter worth about $3,525,000. HighTower Advisors LLC bought a new position in Genmab A/S during the third quarter valued at about $273,000. Verition Fund Management LLC acquired a new position in Genmab A/S in the 3rd quarter valued at approximately $709,000. Finally, FMR LLC lifted its position in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company's stock worth $6,782,000 after acquiring an additional 33,076 shares during the period. 7.07% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a report on Thursday, February 13th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, Truist Financial reduced their target price on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a report on Tuesday, March 11th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Genmab A/S has an average rating of "Moderate Buy" and a consensus target price of $41.33.

Remove Ads

Genmab A/S Stock Down 1.2 %

NASDAQ:GMAB traded down $0.23 during trading hours on Tuesday, hitting $19.06. 1,209,214 shares of the company's stock traded hands, compared to its average volume of 920,348. The business's fifty day simple moving average is $20.94 and its two-hundred day simple moving average is $22.00. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.02. The firm has a market cap of $12.61 billion, a P/E ratio of 10.95, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, analysts expect that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.